PBYI vs. KINS
PBYI (Puma Biotechnology, Inc.) and KINS (Kingstone Companies, Inc.) are both stocks. PBYI operates in Biotechnology (Healthcare), while KINS operates in Insurance - Property & Casualty (Financial Services). Over the past 10 years, PBYI returned -12.52%/yr vs 9.19%/yr for KINS. At a 0.06 correlation, their price movements are largely independent.
Performance
PBYI vs. KINS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PBYI achieves a 35.13% return, which is significantly higher than KINS's 2.85% return. Over the past 10 years, PBYI has underperformed KINS with an annualized return of -12.52%, while KINS has yielded a comparatively higher 9.19% annualized return.
PBYI
- 1D
- 4.96%
- 1M
- 13.56%
- YTD
- 35.13%
- 6M
- 36.04%
- 1Y
- 140.00%
- 3Y*
- 31.32%
- 5Y*
- -4.08%
- 10Y*
- -12.52%
KINS
- 1D
- 2.63%
- 1M
- 8.04%
- YTD
- 2.85%
- 6M
- -0.92%
- 1Y
- 11.13%
- 3Y*
- 145.34%
- 5Y*
- 17.48%
- 10Y*
- 9.19%
PBYI vs. KINS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PBYI Puma Biotechnology, Inc. | 35.13% | 95.08% | -29.56% | 2.36% | 39.14% | -70.37% | 17.26% | -57.00% | -79.41% | 221.99% |
KINS Kingstone Companies, Inc. | 2.85% | 11.54% | 613.15% | 57.78% | -72.27% | -22.97% | -11.56% | -54.74% | -3.80% | 39.37% |
Correlation
The correlation between PBYI and KINS is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.09 |
Correlation (All Time) Calculated using the full available price history since Apr 24, 2012 | 0.06 |
The correlation between PBYI and KINS shifts across timeframes, from 0.06 (all time) to 0.18 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
PBYI:
$408.79M
KINS:
$248.60M
PBYI:
$0.48
KINS:
-$399.22
PBYI:
1.80
KINS:
0.00
PBYI:
3.18
KINS:
0.00
PBYI:
$227.21M
KINS:
$59.92B
PBYI:
$169.14M
KINS:
$100.92M
PBYI:
$46.97M
KINS:
-$6.57B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PBYI vs. KINS — Risk / Return Rank
PBYI
KINS
PBYI vs. KINS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Puma Biotechnology, Inc. (PBYI) and Kingstone Companies, Inc. (KINS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PBYI | KINS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.75 | ||
| Sortino ratioReturn per unit of downside risk | +1.89 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.08 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 5.46 | 0.46 | +5.00 |
| Martin ratioReturn relative to average drawdown | 12.67 | 0.99 | +11.67 |
Loading charts...
Drawdowns
PBYI vs. KINS - Drawdown Comparison
The maximum PBYI drawdown since its inception was -99.40%, roughly equal to the maximum KINS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for PBYI and KINS.
Loading charts...
Drawdown Indicators
| PBYI | KINS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.40% | -96.97% | -2.43% |
Max Drawdown (1Y)Largest decline over 1 year | -25.78% | -24.22% | -1.56% |
Max Drawdown (3Y)Largest decline over 3 years | -69.59% | -38.84% | -30.75% |
Max Drawdown (5Y)Largest decline over 5 years | -82.97% | -90.60% | +7.63% |
Max Drawdown (10Y)Largest decline over 10 years | -98.76% | -96.20% | -2.56% |
Current DrawdownCurrent decline from peak | -97.08% | -19.59% | -77.49% |
Average DrawdownAverage peak-to-trough decline | -74.48% | -49.24% | -25.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.10% | 11.23% | -0.13% |
Volatility
PBYI vs. KINS - Volatility Comparison
Puma Biotechnology, Inc. (PBYI) has a higher volatility of 10.58% compared to Kingstone Companies, Inc. (KINS) at 7.92%. This indicates that PBYI's price experiences larger fluctuations and is considered to be riskier than KINS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PBYI | KINS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.58% | 7.92% | +2.66% |
Volatility (6M)Calculated over the trailing 6-month period | 41.88% | 28.57% | +13.31% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.36% | 39.63% | +29.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 75.89% | 72.73% | +3.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 80.60% | 59.37% | +21.23% |
Dividends
PBYI vs. KINS - Dividend Comparison
PBYI has not paid dividends to shareholders, while KINS's dividend yield for the trailing twelve months is around 1.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KINS Kingstone Companies, Inc. | 1.16% | 0.59% | 0.00% | 0.00% | 8.89% | 3.20% | 2.74% | 4.19% | 2.26% | 1.61% | 1.82% | 2.36% |
PBYI Puma Biotechnology, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PBYI vs. KINS - Financials Comparison
This section allows you to compare key financial metrics between Puma Biotechnology, Inc. and Kingstone Companies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PBYI vs. KINS - Profitability Comparison
PBYI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a gross profit of 34.40M and revenue of 44.80M. Therefore, the gross margin over that period was 76.8%.
KINS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported a gross profit of 0.00 and revenue of 59.78B. Therefore, the gross margin over that period was 0.0%.
PBYI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported an operating income of -3.83M and revenue of 44.80M, resulting in an operating margin of -8.5%.
KINS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported an operating income of 0.00 and revenue of 59.78B, resulting in an operating margin of 0.0%.
PBYI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a net income of -3.80M and revenue of 44.80M, resulting in a net margin of -8.5%.
KINS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported a net income of -5.81B and revenue of 59.78B, resulting in a net margin of -9.7%.
Frequently Asked Questions
PBYI and KINS have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PBYI has higher volatility (10.58%) compared to KINS (7.92%). In terms of maximum drawdown, PBYI dropped -99.40% vs KINS's -96.97%.
PBYI currently has the higher Sharpe Ratio (2.03 vs 0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PBYI and KINS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer